| Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma DA Hofman, J Ruiz-Orera, I Yannuzzi, R Murugesan, A Brown, ... Molecular Cell 84 (2), 261-276. e18, 2024 | 34 | 2024 |
| Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch AM Cornel, E Dunnebach, DA Hofman, S Das, S Sengupta, ... Journal for Immunotherapy of Cancer 10 (12), e005002, 2022 | 26 | 2022 |
| Mutation signatures of pediatric acute myeloid leukemia and normal blood progenitors associated with differential patient outcomes AM Brandsma, EJM Bertrums, MJ van Roosmalen, DA Hofman, R Oka, ... Blood cancer discovery 2 (5), 484-499, 2021 | 16 | 2021 |
| Translational readthrough of nonsense mutant TP53 by mRNA incorporation of 5-Fluorouridine M Palomar-Siles, A Heldin, M Zhang, C Strandgren, V Yurevych, ... Cell Death & Disease 13 (11), 997, 2022 | 15 | 2022 |
| Mutation signatures of pediatric acute myeloid leukemia and normal blood progenitors associated with differential patient outcomes. Blood Cancer Discov. 2, 484–499 AM Brandsma, EJM Bertrums, MJ van Roosmalen, DA Hofman, R Oka, ... BCD-21-0010, 2021 | 5 | 2021 |
| The neo-open reading frame peptides that comprise the tumor framome are a rich source of neoantigens for cancer immunotherapy MV Martin, S Aguilar-Rosas, K Franke, M Pieterse, J Langelaar, ... Cancer immunology research 12 (6), 759-778, 2024 | 3 | 2024 |
| Microproteins in cancer: identification, biological functions, and clinical implications DA Hofman, JR Prensner, S van Heesch Trends in Genetics, 2024 | 2 | 2024 |
| MDB-32. Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma D Hofman, J Ruiz-Orera, I Yannuzzi, R Murugesan, J van Dinter, ... Neuro-Oncology 25 (Suppl 1), i69, 2023 | 1 | 2023 |
| Abstract IA002: Targeting senescence heterogeneity against cancer therapy-resistance and metastases DA Putavet, J Lehmann, B Subtil, D Hofman, MP Baar, PLJ de Keizer Cancer Research 81 (5_Supplement), IA002-IA002, 2021 | | 2021 |
Sebastiaan van HeeschGroup Leader at Princess Máxima Center for Pediatric OncologyZweryfikowany adres z prinsesmaximacentrum.nl